Target- |
Mechanism- |
|
|
|
|
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
|
|
|
|
Active Indication- |
|
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
A First-in-human, Double-blind, Placebo-controlled, Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Intravenous Doses of HM201 (Pegylated Human Adrenomedullin) in Healthy Subjects (Adults)
This will be a single centre, Phase 1, Placebo-controlled, Randomized, Doubleblind, SAD & MAD Study to Assess the Safety, Tolerability and PK of HM201 in Healthy Subjects.
100 Clinical Results associated with Himuka AM Pharma Corp.
0 Patents (Medical) associated with Himuka AM Pharma Corp.
100 Deals associated with Himuka AM Pharma Corp.
100 Translational Medicine associated with Himuka AM Pharma Corp.